Salarius Pharmaceuticals, Inc.
SLRX
$5.77
$0.458.46%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 849.20K | 1.64M | 1.31M | 869.20K | 1.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 965.60K | 1.72M | 1.49M | 1.01M | 1.47M |
| Operating Income | -965.60K | -1.72M | -1.49M | -1.01M | -1.47M |
| Income Before Tax | -957.80K | -1.71M | -1.46M | -972.10K | -1.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -957.80K | -1.71M | -1.46M | -972.10K | -1.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -957.80K | -1.71M | -1.46M | -972.10K | -1.42M |
| EBIT | -965.60K | -1.72M | -1.49M | -1.01M | -1.47M |
| EBITDA | -964.50K | -1.72M | -1.49M | -1.01M | -1.47M |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |